trending Market Intelligence /marketintelligence/en/news-insights/trending/pYSU1DWN18cpQqlekia8UA2 content esgSubNav
In This List

Aprea Therapeutics raises $97.8M in IPO

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Aprea Therapeutics raises $97.8M in IPO

Aprea Therapeutics Inc. raised about $97.8 million in gross proceeds from its IPO on the Nasdaq Global Select Market.

The Boston-based biopharmaceutical company sold 6,516,667 common shares at $15 apiece. This includes an additional 850,000 shares purchased by the underwriters as part of their overallotment option.

Aprea's shares began trading on the exchange under the ticker symbol APRE on Oct. 3.

J.P. Morgan, Morgan Stanley and RBC Capital Markets acted as joint book-running managers for the offering.

Aprea Therapeutics develops therapies for blood cancers such as myelodysplastic syndromes and acute myeloid leukemia.